Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Merck
Medtronic
Dow
Express Scripts

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

NOVOLOG MIX 50/50 Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for NOVOLOG MIX 50/50

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Gan and Lee Pharmaceuticals, USAPhase 1
Texas Diabetes & Endocrinology, P.A.Phase 3
Mylan GmbHPhase 3

See all NOVOLOG MIX 50/50 clinical trials

Recent Litigation for NOVOLOG MIX 50/50

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
Novo Nordisk Inc. v. Teva Pharmaceuticals USA, Inc.2017-03-03
SMITH v. NOVO NORDISK INC.2016-08-08

See all NOVOLOG MIX 50/50 litigation

Company Disclosures: US Patents for NOVOLOG MIX 50/50

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Basgsvaerd, DK) 2013-08-20 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-04-08 DISCN company
Novo Nordisk Inc NOVOLOG MIX 50/50 insulin aspart protamine recombinant; insulin aspart recombinant INJECTABLE;SUBCUTANEOUS 021810 001 2017-11-21   Start Trial Novo Nordisk A/S (Bagsvaerd, DK) 2014-12-02 DISCN company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for NOVOLOG MIX 50/50

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132006901385693 Italy   Start Trial PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTAMINATA NEL RAPPORTO 70/30(NOVOMIX 70); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/017-018-019-020-021-022, 20051005
SPC/GB99/045 United Kingdom   Start Trial SPC/GB99/045: 20060829, EXPIRES: 20110828
132006901385692 Italy   Start Trial PRODUCT NAME: SOSPENSIONE CONTENENTE INSULINA ASPART SOLUBILE E CRISTALLI DI INSULINA ASPART PROTOMINATA NEL RAPPORTO 50/50(NOVOMIX 50); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/142/011-012-013-014-015-016, 20051005
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Baxter
Mallinckrodt
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.